SETD2 and central nervous system cancer: For instance, SETD2 mutations are found in 10% of KIRC [16], 9% of non-small cell lung carcinomas [54], 15% of pediatric high-grade gliomas and 8% of adult high-grade gliomas [55], whereas mutations in DNMT3A are observed in over 20% acute monocytic leukemias [15].